HBVCure New
Meeting category
Date(s)
13 Nov 2024
Program Language
English
Location
San Diego , United States
Meeting type
In-person Workshop
Organizer

International Workshop on HBV Cure 2024

Related Enduring Materials

Enduring Materials
Virtual Program Book | HBV Cure 2024
Session 1: Predictors of Treatment Outcome -
Session Chairs
RNA Interference Combined with Immune Modulation: Are There Clinical Features That Identify HBsAg Loss?
Ed Gane, MBChB, MD, FRACP, FAASLD, MNZM
University of Auckland, New Zealand
Sustainability of HBsAg Loss After Treatment: When Do We Call It Functional Cure?
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Immunological Editing to Drive HBsAg Production from Integrated HBV DNA vs. Infected Hepatocytes
Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
10:10 AM
Coffee Break
Session 2: Intrahepatic Insights and Peripheral Biomarkers of Therapeutic Mechanisms of Action -
Insights from Intrahepatic Analysis in Clinical Trials for Chronic Hepatitis B
Jordan Feld, MD, MPH
Toronto Centre for Liver Disease, Canada
Intrahepatic Landscape in the Delta-Infected, Bulevirtide-Treated Liver
Maura Dandri, PhD
University of Hamburg, Germany
Next Generation Tests for HBcAg and HBcrAg - Increased Sensitivity and Utility?
Mark Sulkowski, MD
Johns Hopkins University, United States
12:00 PM
Lunch
Session 3: Immunology and Immunotherapy -
Atypical Antibody and B Cell Responses in Chronic Viral Infection
Mansun Law, PhD
The Scripps Research Institute, United States
Additive Benefit of Mab in siRNA + IFN-α Combinations
Carey Hwang, MD, PhD
Vir Biotechnology, Inc., United States
PK and Efficacy of Unmodified MAb in Chronic Hepatitis B & D
Hassan Javanbakht, PhD
Bluejay Therapeutics, United States
Therapeutic Vaccine with Novel Checkpoint Inhibition
Sue Currie, PhD
Virion Therapeutics, LLC, United States
HBsAg Levels and T Cell Boost in Patients with HBsAg Decline
Nadège Pelletier, PhD
Barinthus Bio, United Kingdom
TCR Gene Therapy in Clinical Application for Chronic Hepatitis B and HBV-Related HCC
Karin Wisskirchen
SCG Cell Therapy GmbH, Germany
Session 4: Virology and DAAs -
Prospects for Gene Editing in CHB Cure Regimens
Fabien Zoulim, MD, PhD
Lyon I University / Hospices Civils de Lyon / INSERM, France
Strategies and Potential for siRNA + ASO Combinations
Imdusiran Combinations Achieving HBsAg Loss
Karen Sims, MD, PhD
Arbutus Biopharma, United States
Similarities and Differences in Using the TLR7 Agonist Ruzotolimod vs. PEGylated IFN-α in Combination with the HBV siRNA Xalnesiran
Rémi Kazma, MD, PhD
Roche Innovation Center Basel, Switzerland
Efficacy of Cams across Patient Cohorts: HBeAg+ vs. HBeAg-
Tse-I Lin, D.Phil
Aligos Therapeutics, Belgium
Durability of HDV RNA Loss vs Decline after Long-Term Bulevirtide Treatment / IFN + Bulevirtide - Curative Strategies for HDV
Dmitry Manuilov, MD
Gilead Sciences, Germany
Overview
Thank you!

We are pleased to reflect on the highly successful workshop for the International Workshop on HBV Cure 2024, which took place as an in-person workshop on 13 November in San Diego, US. Enduring Materials will be available shortly.

The Program Chair and organizers would like to thank the speakers, chairs, and all participants for their contribution to this meeting!

Special thanks to the all the workshop support. Without their contribution, this workshop would not have been made possible.

The International Workshop on HBV Cure 2024 was fully compliant by EthicalMedTech, underscoring our commitment to maintaining the highest ethical standards. 

To stay updated on the latest developments, make sure you are signed up for our newsletter

​​​​Welcome

The International Workshop on HBV Cure 2024 took place in San Diego, US, on Wednesday 13 November 2024 - just before the AASLD liver meeting. 

Since 2014, the International Workshop on HBV Cure has been a scientific platform acting as a catalyst to accelerate the progress for achieving a cure. Around the globe, more than 250 million people live with hepatitis B (HBV). The purpose of the workshop is to inform the participants about the developments in the work to find a cure for HBV. The meeting will be highly interactive with input from experts out of the arena of basic, translational, and clinical HBV research.

The field of HBV treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available provide great hopes for decreasing the burden of the disease, simplifying treatment, and potentially curing and eradicating HBV infection.

In order to optimize curative treatment for HBV, outstanding speakers from around the globe will share the newest therapeutic options for viral hepatitis, and experts will discuss the path forward to cure this deadly disease, leading to liver cirrhosis and liver cancer. Questions on which endpoints to use in therapeutic trials and how to combine different agents targeting the virus and/or immune system will be extensively discussed.

This workshop also brings together global inter-disciplinary experts to provide a framework for how academia and industry should collaborate to achieve the goal of curing hepatitis B.

Program Directors
Harry Janssen 2019
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
General Information
Venue
The confirmed venue for the HBV Cure 2024 is at the following location:

Horton Grand Hotel
311 Island Avenue
San Diego 92101
California

Distance from San Diego International Airport: 5.5 km (10 minutes)
Unique Features
- Invited lectures from international experts

- Interactive roundtable discussions

- Ample time for discussion
Who should attend?
- Clinicians
- Researchers
- Academia
- Industry
- Government representatives
Meeting Objectives
The objectives of this workshop are to:

- Discuss how to reach an HBV functional cure with newly developed agents targeting the immune system or the viral replication cycle;
- Develop endpoints and better biomarkers for these studies; and
- Discuss how new agents should be combined to reach the goal of a functional cure.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.

Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Practical Information
Certificate of Attedance
A certificate of attendance will be sent to participants that successfully complete the program and post-meeting survey.
Language
The official language of the meeting is English.
Accomodation
Accommodation is not included in the registration fee.
Photographs, Audio, and Visual Recording
Photographs, audio, and video recordings are not permitted at the official workshop sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Liability and Insurance
By registering for the workshop participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, AME and VE, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. AME and VE disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Committees
Program Directors
Harry Janssen 2019
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Organizing Committee
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop and identify interesting topics and candidate speakers.
Scientific Program Coordinator
Support
Silver Level
Bronze Level

Support Our Initiative

Financial backing helps us deliver an impactful meeting experience for the benefit of healthcare professionals, researchers, and community representatives involved in HBV Cure.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Brenda Evan via Brenda.Evan@amededu.com
 
Benefits of Support 
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Non-commercial interviews with company representatives
  • Verbal acknowledgment during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Company acknowledgment on printed meeting materials including but not limited to banners and the program book
  • Digital and printed advertising opportunities 
  • Social media shout-outs
  • Logo on the conference bag 

 
*Subject to the support level

Endorsers
Media
Invitation to Join the International Workshop on HBV Cure 2024

Invitation from Harry Janssen, MD, PhD, Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada and Adam Gehring, PhD, Toronto Centre for Liver Disease, Canada.

Previous Editions
Language